Cargando…

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months

OBJECTIVE: To analyze changes in T-helper (Th) subsets, T-regulatory (Treg) cell percentages and function, and mRNA levels of immunologically relevant molecules during a 24-month follow-up after alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: Multicente...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Mercanti, Stefania, Rolla, Simona, Cucci, Angele, Bardina, Valentina, Cocco, Eleonora, Vladic, Anton, Soldo-Butkovic, Silva, Habek, Mario, Adamec, Ivan, Horakova, Dana, Annovazzi, Pietro, Novelli, Francesco, Durelli, Luca, Clerico, Marinella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723135/ https://www.ncbi.nlm.nih.gov/pubmed/26819963 http://dx.doi.org/10.1212/NXI.0000000000000194

Ejemplares similares

Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up
por: Rolla, Simona, et al.
Publicado: (2022)

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
por: Rolla, Simona, et al.
Publicado: (2020)

Natalizumab in Multiple Sclerosis: Long-Term Management
por: Clerico, Marinella, et al.
Publicado: (2017)

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months
Publicado: (2016)

Tongue somatosensory evoked potentials reflect midbrain involvement in patients with clinically isolated syndrome
por: Krbot Skorić, Magdalena, et al.
Publicado: (2016)

The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View
por: Maglione, Alessandro, et al.
Publicado: (2019)

A real‐world study of alemtuzumab in a cohort of Italian patients
por: Russo, Cinzia Valeria, et al.
Publicado: (2021)

Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis
por: Iannello, Andrea, et al.
Publicado: (2019)

Chickenpox and asymptomatic COVID-19 after first cycle of alemtuzumab for multiple sclerosis
por: Habek, Mario
Publicado: (2021)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017)

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment
por: Haas, Jürgen, et al.
Publicado: (2019)

Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features
por: Pariani, Nadia, et al.
Publicado: (2018)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Host Genetics and Gut Microbiome: Perspectives for Multiple Sclerosis
por: Maglione, Alessandro, et al.
Publicado: (2021)

Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question
por: De Mercanti, Stefania Federica, et al.
Publicado: (2020)

POSTERIOR PENETRATING INJURY OF THE NECK: A CASE REPORT
por: Koruga, Nenad, et al.
Publicado: (2018)

Computational modeling of the immune response in multiple sclerosis using epimod framework
por: Pernice, Simone, et al.
Publicado: (2020)

Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series
por: De Mercanti, Stefania F., et al.
Publicado: (2021)

Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
por: Maglione, Alessandro, et al.
Publicado: (2022)

Miller Fisher syndrome following Pfizer COVID-19 vaccine
por: Abičić, Ana, et al.
Publicado: (2021)

25 (OH) D3 levels, incidence and recurrence of different clinical forms of benig paroxysmal positional vertigo()
por: Maslovara, Sinisa, et al.
Publicado: (2017)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Alemtuzumab in Covid era
por: Iovino, Aniello, et al.
Publicado: (2021)

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis
por: Phelps, Richard, et al.
Publicado: (2019)

Feeding the gut microbiome: impact on multiple sclerosis
por: Bronzini, Matteo, et al.
Publicado: (2023)

FACTORS AFFECTING OUTCOME IN THE TREATMENT OF GLIOBLASTOMA
por: Koruga, Nenad, et al.
Publicado: (2021)

Alemtuzumab in the up-front setting
por: Kaufman, Matthew, et al.
Publicado: (2008)

Alemtuzumab in chronic lymphocytic leukemia
por: Fraser, G., et al.
Publicado: (2007)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Alemtuzumab in refractory Sézary syndrome
por: Reifs, Carmen María Alcántara, et al.
Publicado: (2016)

Long-lasting neutralizing antibodies and T cell response after the third dose of mRNA anti-SARS-CoV-2 vaccine in multiple sclerosis
por: Maglione, Alessandro, et al.
Publicado: (2023)

Online Validation of a Battery of Questionnaires for the Assessment of Family Functioning and Related Factors
por: Lavorgna, Luigi, et al.
Publicado: (2020)

Family Functioning and Multiple Sclerosis: Study Protocol of a Multicentric Italian Project
por: Di Tella, Marialaura, et al.
Publicado: (2021)

New-Onset Ocular Myasthenia Gravis After Booster Dose of COVID-19 Vaccine
por: Abicic, Ana, et al.
Publicado: (2022)

Alemtuzumab induction in pediatric kidney transplantation
por: Kaabak, Michael M, et al.
Publicado: (2013)

Long-term efficacy of alemtuzumab in polymyositis
por: Ruck, Tobias, et al.
Publicado: (2015)

ALEMTUZUMAB FOR CHRONIC LUNG ALLOGRAFT DYSFUNCTION
por: Girgis, Reda, et al.
Publicado: (2020)

Alemtuzumab: Infections: 4 case reports
Publicado: (2020)

Inclusion Body Myositis Treated with Alemtuzumab
por: Sá, Juliana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tncub011nqomg5bprfnbmpuhom